Advanced Parkinsons Disease

The Parkinson's-Reversing Breakthrough

Parkinson Disease Therapy

Get Instant Access

Selegiline has mild to moderate benefit as adjunct therapy to levodopa in advanced PD patients and is approved by the FDA in the United States for this indication. In a small double-blind placebo-controlled trial (79) of selegiline 10mg/day in PD subjects (n = 38) on stable levodopa doses, selegiline reduced daily levodopa dosage requirements (P < 0.05) and significantly improved tremor (P = 0.02) over eight weeks. Thirty subjects (selegiline n = 18, placebo n = 12) completed a 16-month follow-up (79). Both mean levodopa dosage (-133 mg/day) and dosing frequency were significantly reduced in the selegiline-treated group.

Significantly less end-of-dose akinesia was reported in double-blind crossover trials with selegiline (80,81). Golbe et al. (82) randomized 96 PD patients with motor fluctuations that could not be improved with levodopa adjustments to selegiline 10 mg/day or placebo. Mean hourly symptom control in subjects randomized to selegiline was significantly improved compared to placebo (58% vs. 26%; P < 0.01). On average, patients had one hour more on time with selegiline 10 mg/day (82). Adjunct use of selegiline reduced daily levodopa requirements by 10% to 25% (79-82). Selegiline may worsen levodopa-induced dyskinesia but once levodopa dosage adjustments are made, they are typically no worse than at baseline. Nearly 60% of subjects receiving selegiline and 30% treated with placebo reported worsened dysk-inesia within three days after starting treatment (82), with most subjects reporting improvement after reduction of the levodopa dose.

A seven-year extension of the original Palhagen study (72,83) reported 140 of the original 157 PD subjects who participated in the initial study; all were treated with levodopa and randomized to receive selegiline 10 mg/day or placebo. Selegiline slowed disease progression as measured by UPDRS total scores (P = 0.003), motor scores (P = 0.002), and ADL scores (P = 0.0002) compared with placebo. After five years, subjects on placebo had mean UPDRS total scores that were 10 points worse (P = 0.07) and were receiving 19% more levodopa (P = 0.0002) than those treated with selegiline. Wearing off fluctuations were experienced by 27% of subjects, with a trend for fluctuations to be less common (20% vs. 34%; P = 0.053) and appear later (p = 0.076) in the selegiline group over the entire seven years. Dyskinesia developed in 37% of subjects, with no significant difference in frequency (selegiline 35%, placebo 40%) or time to appearance between groups. Nausea, but not hallucinations or diarrhea, was more common in the selegiline group (24% vs. 10%, P = 0.033). This study provided evidence of long-term benefit and suggests that selegiline may reduce progression of disability in PD (83).

Was this article helpful?

0 0

Post a comment